August, 2017—The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO Inc. (“REGENXBIO”), and OrbiMed today announced the formation and launch of Prevail Therapeutics, Inc., (“Prevail”), a new company focused on discovering and developing novel biologic...
August, 2017—Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson’s disease (PD).
